Related references
Note: Only part of the references are listed.Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
Gael S. Roth et al.
EUROPEAN JOURNAL OF CANCER (2023)
Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation
Ahmed W. Moawad et al.
SCIENTIFIC DATA (2023)
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
Carmelo Laface et al.
CANCERS (2023)
State of the art and perspectives in pediatric hepatocellular carcinoma
Graziana Digiacomo et al.
BIOCHEMICAL PHARMACOLOGY (2023)
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma
Dong-yang Ding et al.
BRITISH JOURNAL OF CANCER (2023)
Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review
Beata Szefler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis
Takanori Miyoshi et al.
SUPPORTIVE CARE IN CANCER (2022)
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Yongkun Sun et al.
LIVER CANCER (2022)
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo et al.
LIVER CANCER (2022)
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Hidekatsu Kuroda et al.
LIVER CANCER (2022)
The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion
Masaki Kaibori et al.
CANCER INVESTIGATION (2022)
Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells
Sae Hamaya et al.
ANTICANCER RESEARCH (2022)
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma
Qiao Yang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies
Nawar Al Nasrallah et al.
FRONTIERS IN ONCOLOGY (2022)
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
Do-Youn Oh et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022
Shihao Su et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin
Maria Konoshenko et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted
Reem Ali et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Current epidemiology of cholangiocarcinoma in Western countries
Mathew Vithayathil et al.
JOURNAL OF HEPATOLOGY (2022)
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
Sunisa Prasopporn et al.
FRONTIERS IN ONCOLOGY (2022)
Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Weiwei Li et al.
FRONTIERS IN ONCOLOGY (2022)
YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation
Chen-Song Huang et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2022)
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Thierry de Baere et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2022)
Hepatocellular carcinoma
Arndt Vogel et al.
LANCET (2022)
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
Carmelo Laface et al.
CANCERS (2022)
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Liwei Sun et al.
FRONTIERS IN ONCOLOGY (2022)
Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Yuliannis Lugones et al.
BIOMOLECULES (2022)
Cisplatin for cancer therapy and overcoming chemoresistance
Ranmali Ranasinghe et al.
HELIYON (2022)
A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma
Oyunjargal Baterdene et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2022)
Cisplatin in cancer treatment
Andrea M. P. Romani
BIOCHEMICAL PHARMACOLOGY (2022)
The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial
Panot Sainamthip et al.
JCO GLOBAL ONCOLOGY (2022)
MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma
Xiyang Wei et al.
HEPATOLOGY (2021)
Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature
Kyoko Oura et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?
Antonio Ruggiero et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma
Ahmed Montasser et al.
HISTOPATHOLOGY (2021)
Natural products: potential treatments for cisplatin-induced nephrotoxicity
Chun-yan Fang et al.
ACTA PHARMACOLOGICA SINICA (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
Aditi Jain et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Hsa-circRNA-G004213 promotes cisplatin sensitivity by regulating miR-513b-5p/PRPF39 in liver cancer
Ling Qin et al.
MOLECULAR MEDICINE REPORTS (2021)
HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma
Zhan-Sheng Zhang et al.
CELL BIOLOGY INTERNATIONAL (2021)
Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment
Robert Csaba Kiss et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art
Carmelo Laface et al.
CANCERS (2021)
Glutathione-coordinated metal complexes as substrates for cellular transporters
Stephen A. Pearson et al.
METALLOMICS (2021)
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
Alessandro Granito et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity
Alfredo G. Casanova et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
International trends in hepatocellular carcinoma incidence, 1978-2012
Jessica L. Petrick et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
circRNAs and Exosomes: A Mysterious Frontier for Human Cancer
Xuefei Shi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents
Neife Aparecida Guinaim dos Santos et al.
FOOD AND CHEMICAL TOXICOLOGY (2020)
Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer
Alberto Romano et al.
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study
Tetsunari Hase et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma A meta-analysis
Guan-Bao Long et al.
MEDICINE (2020)
Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1
Shenghao Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline
David R. Freyer et al.
LANCET CHILD & ADOLESCENT HEALTH (2020)
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Renata Zajaczkowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cisplatin: The first metal based anticancer drug
Sumit Ghosh
BIOORGANIC CHEMISTRY (2019)
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Yuan Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Masaaki Kondo et al.
BMC CANCER (2019)
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Ludovic Fournel et al.
CANCER LETTERS (2019)
Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule
Fei Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization
Hamdy E. A. Ali et al.
CLINICAL BIOCHEMISTRY (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium
Eva Clemens et al.
LANCET ONCOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity
Vladislav Volarevic et al.
JOURNAL OF BIOMEDICAL SCIENCE (2019)
Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy
Tomaz Makovec
RADIOLOGY AND ONCOLOGY (2019)
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial
Masahiro Hatooka et al.
BMC CANCER (2018)
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
Jong Hwan Choi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity
Tom T. G. Nieskens et al.
DRUG METABOLISM AND DISPOSITION (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Intravenous rocuronium 0.3 mg/kg improves the conditions for tracheal intubation in cats: a randomized, placebo-controlled trial
Daniel M. Sakai et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2018)
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Iman W. Achkar et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Facilitating the Cellular Accumulation of Pt-Based Chemotherapeutic Drugs
Ian Henry Lambert et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Pediatric hepatocellular carcinoma
Rajeev Khanna et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Role of HIF-1 in Cancer Progression: Novel Insights. A Review
Aldo Pezzuto et al.
CURRENT MOLECULAR MEDICINE (2018)
Cisplatin-induced cardiotoxicity with midrange ejection fraction A case report and review of the literature
Yang Hu et al.
MEDICINE (2018)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
Rebecka L. Meyers et al.
LANCET ONCOLOGY (2017)
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
Daniel J. Crona et al.
ONCOLOGIST (2017)
Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
Yanqing Huang et al.
SCIENCE CHINA-LIFE SCIENCES (2017)
The molecular mechanisms of chemoresistance in cancers
Hua-Chuan Zheng
ONCOTARGET (2017)
MiR-488 inhibits proliferation and cisplatin sensibility in non-smallcell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway
Chao Fang et al.
SCIENTIFIC REPORTS (2017)
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Linda Tran et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2017)
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review
Nicolas Kerckhove et al.
FRONTIERS IN PHARMACOLOGY (2017)
Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma
Morihiko Ishizaki et al.
CANCER INVESTIGATION (2017)
Pediatric hepatocellular carcinoma: challenges and solutions
Irene Schmid et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2017)
The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
Antonio Ruggiero et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201
Kiichiro Ninomiya et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy
Trevor McKibbin et al.
SUPPORTIVE CARE IN CANCER (2016)
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
M. Ikeda et al.
ANNALS OF ONCOLOGY (2016)
Activation of apoptosis signalling pathways by reactive oxygen species
Maureen Redza-Dutordoir et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells
Shuichi Kishimoto et al.
BIOMETALS (2016)
The (C)under-barhildren's (H)under-barepatic tumors (I)under-barnternational (C)under-barollaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model
Piotr Czauderna et al.
EUROPEAN JOURNAL OF CANCER (2016)
Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies
Maciej Murawski et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group
Johnnie K. Bass et al.
PEDIATRIC BLOOD & CANCER (2016)
Role of copper transporters in platinum resistance
Deepak Kilari et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2016)
The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer
Jian Zhao et al.
BMC CANCER (2015)
Current Status of Hepatic Arterial Infusion Chemotherapy
Shuntaro Obi et al.
LIVER CANCER (2015)
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)
Masashi Kanai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Angela Callejo et al.
TOXICS (2015)
Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice
Malvika H. Solanki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Thymoquinone attenuates cisplatin-induced hepatotoxicity via nuclear factor kappa- β
Abdulrahman L. Al-Malki et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2014)
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma
Atsushi Hagihara et al.
CANCER SCIENCE (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin
Nasma D. Eljack et al.
METALLOMICS (2014)
Neonatal Medical Exposures and Characteristics of Low Birth Weight Hepatoblastoma Cases: A Report From the Children's Oncology Group
Lucie M. Turcotte et al.
PEDIATRIC BLOOD & CANCER (2014)
Association of Serum MicroRNA Expression in Hepatocellular Carcinomas Treated with Transarterial Chemoembolization and Patient Survival
Mei Liu et al.
PLOS ONE (2014)
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
C. R. R. Rocha et al.
CELL DEATH & DISEASE (2014)
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
Hiroshi Kawaguchi et al.
Journal of Ovarian Research (2014)
Comparison of Short and Continuous Hydration Regimen in Chemotherapy Containing Intermediate- to High-Dose Cisplatin
Akira Ouchi et al.
JOURNAL OF ONCOLOGY (2014)
Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation
Malvika H. Solanki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Visualizing Inhibition of Nucleosome Mobility and Transcription by Cisplatin-DNA Interstrand Crosslinks in Live Mammalian Cells
Guangyu Zhu et al.
CANCER RESEARCH (2013)
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)
Chigusa Morizane et al.
CANCER SCIENCE (2013)
The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease
Natalie K. Y. Wee et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
Laura Astolfi et al.
ONCOLOGY REPORTS (2013)
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Rossella Marullo et al.
PLOS ONE (2013)
Therapeutic efficacy of transarterial chemo-embolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma
Kazuhiro Kasai et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human Cells
Kristin D. Ivy et al.
MOLECULAR PHARMACOLOGY (2013)
Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy
Subash C. Gupta et al.
ANTIOXIDANTS & REDOX SIGNALING (2012)
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
Michelle Martinez-Rivera et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy
Macus Tien Kuo et al.
CANCER RESEARCH (2012)
Transarterial Chemoembolization With Cisplatin as Second-Line Treatment for Hepatocellular Carcinoma Unresponsive to Chemoembolization With Epirubicin-Lipiodol Emulsion
Noboru Maeda et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2012)
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells
Ganna V. Kalayda et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma
Irene Schmid et al.
PEDIATRIC BLOOD & CANCER (2012)
Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes
Ding-Wu Shen et al.
PHARMACOLOGICAL REVIEWS (2012)
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic
Armelle Lavole et al.
BULLETIN DU CANCER (2012)
A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma
Hiraku Yodono et al.
ANTI-CANCER DRUGS (2011)
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma
Beom Kyung Kim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization
Ming-Yen Hsieh et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2011)
Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy
Ashutosh Shrivastava et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
DNA interstrand crosslink repair and cancer
Andrew J. Deans et al.
NATURE REVIEWS CANCER (2011)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics
Ryan C. Todd et al.
CHEMISTRY & BIOLOGY (2010)
Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group
Satkiran Grewal et al.
PEDIATRICS (2010)
Mechanisms of Cisplatin Nephrotoxicity
Ronald P. Miller et al.
TOXINS (2010)
Cellular Responses to Cisplatin-Induced DNA Damage
Alakananda Basu et al.
JOURNAL OF NUCLEIC ACIDS (2010)
Persistent neuropathy after treatment with cisplatin and oxaliplatin
Elke E. M. Brouwers et al.
ACTA ONCOLOGICA (2009)
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
J. W. Valle et al.
BRITISH JOURNAL OF CANCER (2009)
Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats
Koji Yokoo et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2009)
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
K. K. Filipski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Cholangiocarcinoma
Stefania Mosconi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Cisplatin Overdose Toxicities and Management
Roger Y. Tsang et al.
DRUG SAFETY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity
Navjotsingh Pabla et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Interaction of cisplatin with the human organic cation transporter 2
Kelly K. Filipski et al.
CLINICAL CANCER RESEARCH (2008)
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A 1,2-d(GpG) cisplatin intrastrand cross-link influences the rotational and translational setting of DNA in nucleosomes
Matthias Ober et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Transcriptional activation of caspase-6 and-7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity
C. Yang et al.
CELL DEATH AND DIFFERENTIATION (2008)
Cisplatin nephrotoxicity: A review
Xin Yao et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells
B. Zhang et al.
KIDNEY INTERNATIONAL (2007)
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma
Jun Yong Park et al.
CANCER (2007)
Prevention of noise- and drug-induced hearing loss with D-methionine
Kathleen C. M. Campbell et al.
HEARING RESEARCH (2007)
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)
Atsushi Yonezawa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis
Zejia Yang et al.
CLINICAL CANCER RESEARCH (2006)
Functions of human replication protein A (RPA): From DNA replication to DNA damage and stress responses
Yue Zou et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption
EA Neuwelt et al.
PEDIATRIC BLOOD & CANCER (2006)
Role of copper transporters in the uptake and efflux of platinum containing drugs
R Safaei
CANCER LETTERS (2006)
A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity
Manchang Liu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials
P. M. Lopez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development
KRG Knight et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities
SS Byun et al.
BJU INTERNATIONAL (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Risk-adapted treatment for childhood hepatoblastoma:: final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2
G Perilongo et al.
EUROPEAN JOURNAL OF CANCER (2004)
Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells
GL Beretta et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death
K Tsuruya et al.
KIDNEY INTERNATIONAL (2003)
Adult type vs. childhood hepatocellular carcinoma - Are they the same or different lesions? Biology, natural history, prognosis, and treatment
P Czauderna
MEDICAL AND PEDIATRIC ONCOLOGY (2002)
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
S Ishida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
G Ramesh et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Hepatocellular carcinoma in children: Results of the first prospective study of the International Society of Pediatric Oncology Group
P Czauderna et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: Comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion
K Kamada et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2001)
Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach - Results of the first prospective study of the international society of pediatric oncology
J Pritchard et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)